Clinical Trials Browser

Head and Neck Neoplasms × Ipilimumab × 90 days × Clear all

NCT02812524 2026-04-24

Ipilimumab for Head and Neck Cancer Patients

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms